Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

Sanofi’s SNY stock has been trading below its 200-day and 50-day moving averages since early June. On June 23, the stock’s ...

The quest to mitigate disability progression in multiple sclerosis (MS) has long been hindered by our limited understanding ...

Despite this, tolebrutinib slowed time to 6-month confirmed disability worsening (CDW) in relapsing MS by 29% (HR 0.71, 95% CI 0.53-0.95) compared with teriflunomide in pooled GEMINI trial data.

Tolebrutinib was previously granted breakthrough therapy designation by the FDA, based on positive results from the HERCULES phase 3 study in adults with non-relapsing secondary progressive MS.

Tolebrutinib was shown to delay the time to onset of six-month confirmed disability progression by 31% compared to placebo in nrSPMS patients. Results from the phase 3 GEMINI 1 and 2 trials, which ...

WEDNESDAY, April 9, 2025 (HealthDay News) -- Tolebrutinib, a brain-penetrant and bioactive Bruton tyrosine kinase inhibitor that modulates persistent immune activation within the central nervous ...

Tolebrutinib was previously granted breakthrough therapy designation by the FDA, based on positive results from the HERCULES phase 3 study in adults with non-relapsing secondary progressive MS.

Tolebrutinib was previously granted breakthrough therapy designation by the FDA, based on positive results from the HERCULES phase 3 study in adults with non-relapsing secondary progressive MS.

A Cleveland Clinic-led clinical trial of tolebrutinib, an investigational oral Bruton’s tyrosine kinase inhibitor, a group of drugs originally developed to treat lymphomas and related blood disorders, ...